China's leading vaccines group edges towards $1.6bn Hong Kong IPO
This article was originally published in Scrip
Executive Summary
China's largest manufacturer of vaccines has taken the first regulatory step towards a planned initial public offering in Hong Kong that could see it raise close to $1.6 billion.